Article
Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial.
The Lancet. Neurology - 1 Feb 2026
Tariot Pierre N, Lopera Francisco S, Ríos-Romenets Silvia, Sink Kaycee M, Giraldo-Chica Margarita, Acosta-Baena Natalia, Villegas Gustavo, Espinosa Alejandro, Castaño Marisol Londoño, Muñoz Claudia, Ospina Paula, Bocanegra Yamile, Tirado Victoria, Henao Eliana, Cardona Eugenia, Luna Ernesto, Lopez Hugo, Sánchez Gregorio, Collazos Mario Muñoz, Alvarez Sergio, Aguillón David, Hu Nan, Clayton David, Bittner Tobias, Schneider Andres, Dolton Michael, Poon Victor, Nguyen Jonas, Thomas Ronald G, Schneider Lon S, Chen Kewei, Su Yi, Alexander Robert C, Quiroz Yakeel T, Cai Yuqi, Xu Yi Ran, Ostaszewski Beth, Selkoe Dennis J, Ashton Nicholas J, Denkinger Marisa N, Jakimovich Laura J, Doody Rachelle S, Langbaum Jessica B, Reiman Eric M
Abstract excerpt
BACKGROUND: To have maximal benefit, Alzheimer's disease-modifying treatments might need to be started before the onset of clinical symptoms. Mutations of the PSEN1 gene are inherited as fully penetrant, autosomal-dominant traits, which almost always result in the clinical onset of Alzheimer's disease before the age of 65 years. We aimed to evaluate the efficacy, including possible delayed emergence of cognitive...
Read the complete abstract on PubMed